Video

Dr. Velcheti on the Safety of Nemvaleukin in Solid Tumors

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

Vamsidhar Velcheti, MD, associate professor, Department of Medicine, NYU Grossman School of Medicine, director, Thoracic Medical Oncology Program, NYU Langone Health, discusses the safety of nemvaleukin alfa (nemvaleukin) in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial (NCT02799095).

Investigators of ARTISTRY-1 evaluated nemvaleukin both as a monotherapy and in combination with pembrolizumab (Keytruda) in the first-in-human study.

The safety profile of nemvaleukin is similar to other cytokine drugs in its class and the monotherapy safety profile is very promising, Velcheti says. Additionally, nemvaleukin in combination with pembrolizumab had no significant increase in immune-related toxicities, Velcheti explains.

As of the data readout, approximately 3% of patients on the monotherapy discontinued treatment because of the drug, Velcheti continues. No evidence of cytokine release syndrome or capillary leak syndrome were noted in the trial, Velcheti concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center